Vanguard Therapeutics Overview
- Year Founded
-
2009
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
3
Vanguard Therapeutics General Information
Description
Developer of drug therapy intended for sickle cell disease. The company's oral drug blocks the cell adhesion molecule P-selectin and addresses the problem of sickle red blood cells sticking to the vascular endothelium, enabling doctors to improve blood flow, mitigate acute painful crises, and improve the quality of life of patients with sickle cell disease.
Contact Information
Corporate Office
- 108 Eagle Trace Drive
- Half Moon Bay, CA 94019
- United States
Corporate Office
- 108 Eagle Trace Drive
- Half Moon Bay, CA 94019
- United States
Vanguard Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Accelerator/Incubator | 08-Jan-2020 | Completed | Generating Revenue | |||
| 5. Grant | 01-Jan-2017 | Completed | Generating Revenue | |||
| 4. Grant | 01-Jan-2016 | Completed | Generating Revenue | |||
| 3. Accelerator/Incubator | 01-Jan-2015 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 01-Apr-2014 | Completed | Generating Revenue | |||
| 1. Grant | 01-Jan-2014 | $562K | Completed | Generating Revenue |
Vanguard Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Vanguard Therapeutics Patents
Vanguard Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20180318336-A1 | Pentosan polysulfate sodium for the treatment of sickle cell disease | Inactive | 27-May-2015 | ||
| EP-3302705-A1 | Pentosan polysulfate sodium for the treatment of sickle cell disease | Inactive | 27-May-2015 | ||
| AU-2016267264-A1 | Pentosan polysulfate sodium for the treatment of sickle cell disease | Inactive | 27-May-2015 | ||
| US-20210220390-A1 | Pentosan polysulfate sodium for the treatment of sickle cell disease | Inactive | 27-May-2015 | ||
| EP-3302705-A4 | Pentosan polysulfate sodium for the treatment of sickle cell disease | Inactive | 27-May-2015 | A61K31/737 |
Vanguard Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Vanguard Therapeutics Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| California Life Sciences | Accelerator/Incubator | |||
| QB3 | Accelerator/Incubator | |||
| U.S. Department of Health and Human Services | Government |
Vanguard Therapeutics FAQs
-
When was Vanguard Therapeutics founded?
Vanguard Therapeutics was founded in 2009.
-
Where is Vanguard Therapeutics headquartered?
Vanguard Therapeutics is headquartered in Half Moon Bay, CA.
-
What is the size of Vanguard Therapeutics?
Vanguard Therapeutics has 4 total employees.
-
What industry is Vanguard Therapeutics in?
Vanguard Therapeutics’s primary industry is Drug Discovery.
-
Is Vanguard Therapeutics a private or public company?
Vanguard Therapeutics is a Private company.
-
What is Vanguard Therapeutics’s current revenue?
The current revenue for Vanguard Therapeutics is .
-
Who are Vanguard Therapeutics’s investors?
California Life Sciences, QB3, and U.S. Department of Health and Human Services have invested in Vanguard Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
